Kelly Mok
Overview
Explore the profile of Kelly Mok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yap N, Wong V, Morton C, de Boer R, Baron-Hay S, Blum R, et al.
Intern Med J
. 2024 Oct;
54(11):1894-1897.
PMID: 39467087
This study evaluated patient-reported outcomes (PROs) of Medicine Access Programmes (MAPs) for Australian metastatic breast cancer patients on ribociclib. Limited patient awareness of MAP enrolment was identified, emphasising the need...
2.
Howard J, Siegel L, Mok K, Sibbald S
MedEdPublish (2016)
. 2024 Mar;
10:90.
PMID: 38486580
This article was migrated. The article was marked as recommended. Dermatological concerns are one of the most common presentations in family practice. Residents often feel inadequately prepared to address these...
3.
Thornton J, Rosen C, Davenport M, Mountjoy M, Dorian P, Gouttebarge V, et al.
BMJ Open Sport Exerc Med
. 2023 Jan;
9(1):e001479.
PMID: 36643408
Objectives: Little is known about the impact of elite sport participation on long-term athlete health. We aimed to: (1) describe musculoskeletal, mental health, reproductive/endocrine and cardiovascular characteristics in retired elite...
4.
Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, et al.
Clin Breast Cancer
. 2022 Sep;
22(8):792-800.
PMID: 36151018
Background: International guidelines recommend combining a CDK4/6 inhibitor and endocrine therapy (ET) as first line treatment for hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). Results from MONALEESA-2...
5.
Jeffreys S, Powter B, Balakrishnar B, Mok K, Soon P, Franken A, et al.
Cells
. 2020 Sep;
9(9).
PMID: 32932819
Therapy of hormone receptor positive breast cancer (BCa) generally targets estrogen receptor (ER) function and signaling by reducing estrogen production or by blocking its interaction with the ER. Despite good...
6.
Wilson B, Mok K, Kiely B, Nguyen R, Moylan E
Intern Med J
. 2019 Nov;
49(11):1438-1442.
PMID: 31713335
Combination ribociclib and aromatase inhibitors are currently the preferred treatment in Australia for newly diagnosed hormone receptor positive metastatic breast cancer in the absence of visceral crisis. In our case...
7.
Tognela A, Beith J, Kiely B, Bastick P, Lynch J, Descallar J, et al.
Clin Breast Cancer
. 2015 Feb;
15(4):277-84.
PMID: 25676930
Introduction: The adjuvant trastuzumab trials largely excluded women with small, node-negative, HER2-positive breast cancers. Accordingly, limited data exist regarding the effect of trastuzumab in the management of these patients. Our...
8.
Juraskova I, Jarvis S, Mok K, Peate M, Meiser B, Cheah B, et al.
J Sex Med
. 2013 May;
10(10):2549-58.
PMID: 23635341
Introduction: Almost half of breast cancer survivors experience chronic sexual problems. Despite the negative effects of dyspareunia on physical and overall quality of life, sexual dysfunction remains underreported and undertreated...
9.
Webber K, Mok K, Bennett B, Lloyd A, Friedlander M, Juraskova I, et al.
Oncologist
. 2011 Aug;
16(9):1333-44.
PMID: 21835897
Background: We recently reported that cancer-related fatigue (CRF) after adjuvant breast cancer therapy was prevalent and disabling, but largely self-limiting within 12 months. The current paper describes sexual functioning (SF)...
10.
Mok K, Juraskova I, Friedlander M
Breast
. 2008 May;
17(5):436-40.
PMID: 18479922
There is substantial evidence supporting the adjuvant usage of aromatase inhibitors (AIs) in the treatment of postmenopausal women with early breast cancer. However, the exacerbation of postmenopausal gynaecological symptoms such...